UroSens raises £2m from Longwall Venture Partners, Northstar Ventures, and Esperante to advance cancer diagnostics.
Longwall Venture Partners led the investment round, which will fund clinical trials and commercial development.
£2.0M
UroSens develops proprietary diagnostic immunoassays using urine samples for the detection of prostate and bladder cancer.
UroSens has secured £2m in a new funding round led by Longwall Venture Partners, with participation from existing backers Northstar Ventures and Esperante.
The company develops diagnostic immunoassays designed to detect prostate and bladder cancer from urine samples, aiming to reduce the need for invasive and costly biopsies in clinics.
The newly raised capital will be directed towards advancing clinical trials and accelerating the commercial development of its diagnostic technology.
From the founder
"closing this new investment round marks a significant step forward for UroSens. We are grateful to all of our investors for their continued support."
IC
Ian Campbell
CEO at UroSens
Use of funds
- 01Fund research and development
- 02Fund the next phase of growth
